Anavex Life Sciences Corp.

NASDAQ:AVXL

Biotechnology

Healthcare
$0.72 -1.67%

-$0.04 today

Market cap
$66.69M
Beta
1.12
P/E (TTM)
-5.9
EPS (TTM)
-$0.45
52W Low $2.41High $13.99

Volume 1.06M

Average 1.39M

AVXL Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Anavex Life Sciences Corp.NASDAQ: AVXL

Selling, General & Admin · Q1 FY2026 · quarter ended Dec 2025

Selling, general & admin dips below year-ago levels

Q1 FY2026 selling, general & admin of $2.13M fell 32.4% year over year, behind the +10.2% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 40.1% from the prior quarter. Over 3 fiscal years it compounded at +1.9% a year.

Context

  • Selling, general & admin increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 1 analysts of $0 (-100.0%) for the fiscal year ending Sep 2026, a slowdown from the +25.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterDec 2025
$2.13M-40.1% QoQ
Last fiscal yearSep 2025
$13.82M+25.2% YoY
LTMDec 2025
$12.8M+10.2% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-32.4%-100.0%-67.6 pp
1 year+25.2%-100.0%-125.2 pp
3-year CAGR+1.9%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
13.82M USD
Year-over-year change
+25.2%
4-year CAGR
+11.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How AVXL compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +10.2% is the 5th highest of 10, against a peer median of +6.5%.
  • Over three fiscal years its annual growth of +1.9% compares with a peer median of +4.8%.
AVXL Competitors
Selling, General & Admin for AVXL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ARVNArvinas, Inc.LTM Mar 2026$86.5M USD-47.9%+3.9%96.8%
RGNXREGENXBIO Inc.LTM Mar 2026$83.82M USD+6.5%-1.0%95.4%
VALNValneva SELTM Mar 2026€70.46M EUR-23.0%+9.1%45.1%
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$59.07M USD+263.5%+71.2%—
MGTXMeiraGTx Holdings plcLTM Mar 2026$52.46M USD-2.3%+4.4%65.8%
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$46.46M USD+34.5%+22.2%—
ERASErasca, Inc.LTM Sep 2026$44.05M USD+16.1%+5.3%—
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$31.1M USD-1.0%-11.4%87.5%
ABSIAbsci CorporationLTM Mar 2026$17.68M USD+91.0%—962.7%
AVXLAnavex Life Sciences Corp.LTM Dec 2025$12.8M USD+10.2%+1.9%—
Peer median (excluding AVXL) —+6.5%+4.8%91.5%

Competitors are the stored peer set for AVXL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development32.98M37.92M43.72M41.84M37.59M
Selling, General & Admin9.02M13.07M12.05M11.04M13.82M
Operating Expenses42M50.99M55.76M52.88M51.41M
Depreciation & Amortization00000
EBITDA(37.64M)(47.62M)(46.54M)(43M)(46.38M)
EBITDA Margin—————
Operating Income(42M)(50.99M)(55.76M)(52.88M)(51.41M)
Operating Margin—————
Interest Income26K947K6.52M7.32M4.68M
Interest Expense00964K00
Other Income / Expenses4.36M3.37M8.26M9.88M5.03M
Income Before Tax(37.64M)(47.62M)(47.51M)(43M)(46.38M)
Pre-Tax Margin—————
Income Tax Expense268K358K000
Net Income(37.91M)(47.98M)(47.51M)(43M)(46.38M)
Net Margin—————
EPS (Basic)(0.54)(0.62)(0.60)(0.52)(0.54)
EPS (Diluted)(0.54)(0.62)(0.60)(0.52)(0.54)
Weighted Avg Shares69.8M76.91M79.79M83.47M85.29M
Weighted Avg Shares (Diluted)69.8M76.91M79.79M83.47M85.29M

Anavex Life Sciences Corp.

NASDAQ:AVXL

Intrinsic Alpha fair value

Locked

Current Price

$0.72

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.